Preclinical evaluation of venglustat, a brain-penetrant inhibitor of glucosylceramide synthase, reduced asyn pathology and the associated cognitive decline in mouse models of GBA1-related synucleinopathy (109). Here, GBA1 is linked to synucleinopathy.